RBC Capital analyst Shagun Singh Chadha maintained a Hold rating on Teleflex on January 7 and set a price target of $135.00. The company’s shares closed yesterday at $126.53.

Teleflex announced a major leadership transition effective January 7–8, 2026, with long-time Chairman, President and CEO Liam Kelly departing and board member Stuart Randle, a veteran medical device ...

The purchase is expected to expand Haemonetics’ impact in fast-growing markets for structural heart and endovascular ...

Defense stocks surged Thursday, erasing the prior session's losses, after President Donald Trump floated a sharp increase in ...

Teleflex has parted ways with CEO Liam Kelly and is putting a retired board member in charge of the company on an interim ...

Choose Philadelphia Business Journal as a preferred news source to see more of our reporting on Google.

Teleflex shares fell after the medical technology company said it was parting ways with its chief executive officer, and cut its outlook for the year. The stock was down 13% to $110.36 in late morning ...

Stock futures exhibited mixed performance on Thursday, as market participants braced for key U.S. employment data later in ...

Stuart Randle Appointed Interim President and CEO Board Initiates Search for Permanent CEO Dr. Stephen Klasko Appointed Chairman of the Board Company Provides Update on Preliminary Full Year 2025 Reve ...

Teleflex announced today that Chair, President and CEO Liam Kelly is departing the company, effective immediately.

Teleflex cut its full-year revenue outlook for 2025, citing softer-than-expected demand and order delays. The medical-technologies company on Thursday said it now expects to report revenue of $3.27 ...